-
PDF
- Split View
-
Views
-
Cite
Cite
Sara M. Tolaney, David R. Ziehr, Hao Guo, Mei R. Ng, William T. Barry, Michaela J. Higgins, Steven J. Isakoff, Jane E. Brock, Elena V. Ivanova, Cloud P. Paweletz, Michelle K. Demeo, Nikhil H. Ramaiya, Beth A. Overmoyer, Rakesh K. Jain, Eric P. Winer, Dan G. Duda, Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients, The Oncologist, Volume 26, Issue 8, August 2021, Page e1483, https://doi.org/10.1002/onco.13809
Close - Share Icon Share
The Oncologist 2017;22:25–32; first published on October 27, 2016; doi: 10.1634/theoncologist.2016-0229
In the original publication of this article, the ClinicalTrials.gov trial identifier (ID) was published incorrectly. The online version of the article has been corrected to reflect the accurate trial ID: NCT01738438.
